ID   SCC-4
AC   CVCL_1684
SY   SCC 4; SCC4
DR   BTO; BTO:0003775
DR   CLO; CLO_0008968
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   ATCC; CRL-1624
DR   BCRC; 60142
DR   BCRJ; 0195
DR   BioGRID_ORCS_Cell_line; 1005
DR   BioSample; SAMN01821596
DR   BioSample; SAMN01821663
DR   BioSample; SAMN03471408
DR   BioSample; SAMN10987944
DR   cancercelllines; CVCL_1684
DR   Cell_Model_Passport; SIDM01081
DR   ChEMBL-Cells; CHEMBL3308803
DR   ChEMBL-Targets; CHEMBL1075570
DR   Cosmic; 910904
DR   Cosmic; 921833
DR   Cosmic; 1118794
DR   Cosmic; 1339920
DR   Cosmic; 1608861
DR   Cosmic; 1752767
DR   Cosmic; 2266792
DR   Cosmic; 2513910
DR   Cosmic; 2668291
DR   Cosmic-CLP; 910904
DR   DepMap; ACH-000238
DR   DSMZ; ACC-618
DR   DSMZCellDive; ACC-618
DR   ECACC; 89062002
DR   EGA; EGAS00001000978
DR   GDSC; 910904
DR   GEO; GSM422869
DR   GEO; GSM423672
DR   GEO; GSM827188
DR   GEO; GSM887560
DR   GEO; GSM888643
DR   GEO; GSM1374865
DR   GEO; GSM1670411
DR   IARC_TP53; 1913
DR   IGRhCellID; SCC4%20GSE9585
DR   JCRB; JCRB9118
DR   LiGeA; CCLE_541
DR   LINCS_LDP; LCL-1224
DR   PharmacoDB; SCC4_1355_2019
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_1684
DR   PubChem_Cell_line; CVCL_1684
DR   RCB; RCB0745
DR   Wikidata; Q54952345
RX   DOI=10.1016/B978-0-12-333530-2.50007-1;
RX   PubMed=1394225;
RX   PubMed=2573646;
RX   PubMed=3417487;
RX   PubMed=3458227;
RX   PubMed=6186388;
RX   PubMed=6722007;
RX   PubMed=7214336;
RX   PubMed=8390283;
RX   PubMed=17312569;
RX   PubMed=20014447;
RX   PubMed=20145189;
RX   PubMed=20164919;
RX   PubMed=20215515;
RX   PubMed=21868764;
RX   PubMed=22006338;
RX   PubMed=22460905;
RX   PubMed=24825747;
RX   PubMed=26589293;
RX   PubMed=27397505;
RX   PubMed=29156801;
RX   PubMed=30135316;
RX   PubMed=30894373;
RX   PubMed=30971826;
RX   PubMed=31068700;
RX   PubMed=35839778;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Population: Caucasian.
CC   Doubling time: ~60-70 hours (DSMZ=ACC-618).
CC   HLA typing: A*02:01,02:01; B*07:02,44:03; C*04:01,07:02; DQA1*01:02,02:01; DQB1*02:02,06:02; DRB1*07:01,15:01 (PubMed=26589293).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro151Ser (c.451C>T); ClinVar=VCV000012370; Zygosity=Unspecified (PubMed=8390283).
CC   Omics: Array-based CGH.
CC   Omics: CRISPR phenotypic screen.
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=0%; Native American=0.04%; East Asian, North=0%; East Asian, South=1.1%; South Asian=0.53%; European, North=69.79%; European, South=28.55% (PubMed=30894373).
CC   Discontinued: RCB; RCB0745; true.
CC   Derived from site: In situ; Oral cavity, tongue; UBERON=UBERON_0001723.
ST   Source(s): ATCC; Cosmic-CLP; DSMZ; PubMed=21868764
ST   Amelogenin: X,Y
ST   CSF1PO: 11
ST   D13S317: 11,13
ST   D16S539: 12
ST   D18S51: 15
ST   D19S433: 12,14
ST   D21S11: 32.2
ST   D2S1338: 16,24
ST   D3S1358: 18
ST   D5S818: 13
ST   D7S820: 9,11
ST   D8S1179: 14
ST   FGA: 21,22
ST   Penta D: 12
ST   Penta E: 14
ST   TH01: 9.3
ST   TPOX: 8
ST   vWA: 15,17
DI   NCIt; C4648; Tongue squamous cell carcinoma
DI   ORDO; Orphanet_457252; Squamous cell carcinoma of the oral tongue
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   55Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 40
//
RX   DOI=10.1016/B978-0-12-333530-2.50007-1;
RA   Carey T.E.;
RT   "Head and neck tumor cell lines.";
RL   (In) Atlas of human tumor cell lines; Hay R.J., Park J.-G., Gazdar A.F. (eds.); pp.79-120; Academic Press; New York (1994).
//
RX   PubMed=1394225;
RA   Somers K.D., Merrick M.A., Lopez M.E., Incognito L.S., Schechter G.L.,
RA   Casey G.;
RT   "Frequent p53 mutations in head and neck cancer.";
RL   Cancer Res. 52:5997-6000(1992).
//
RX   PubMed=2573646; DOI=10.1080/09553008914551731;
RA   Weichselbaum R.R., Rotmensch J., Ahmed-Swan S., Beckett M.A.;
RT   "Radiobiological characterization of 53 human tumor cell lines.";
RL   Int. J. Radiat. Biol. 56:553-560(1989).
//
RX   PubMed=3417487; DOI=10.1016/0360-3016(88)90297-0;
RA   Weichselbaum R.R., Beckett M.A., Schwartz J.L., Dritschilo A.;
RT   "Radioresistant tumor cells are present in head and neck carcinomas
RT   that recur after radiotherapy.";
RL   Int. J. Radiat. Oncol. Biol. Phys. 15:575-579(1988).
//
RX   PubMed=3458227; DOI=10.1073/pnas.83.8.2684;
RA   Weichselbaum R.R., Dahlberg W.K., Beckett M.A., Karrison T., Miller D.,
RA   Clark J., Ervin T.J.;
RT   "Radiation-resistant and repair-proficient human tumor cells may be
RT   associated with radiotherapy failure in head- and neck-cancer
RT   patients.";
RL   Proc. Natl. Acad. Sci. U.S.A. 83:2684-2688(1986).
//
RX   PubMed=6186388; DOI=10.1016/0092-8674(82)90324-5;
RA   Wu Y.-J., Parker L.M., Binder N.E., Beckett M.A., Sinard J.H.,
RA   Griffiths C.T., Rheinwald J.G.;
RT   "The mesothelial keratins: a new family of cytoskeletal proteins
RT   identified in cultured mesothelial cells and nonkeratinizing
RT   epithelia.";
RL   Cell 31:693-703(1982).
//
RX   PubMed=6722007; DOI=10.1038/bjc.1984.94;
RA   Weichselbaum R.R., Dahlberg W.K., Little J.B., Ervin T.J., Miller D.,
RA   Hellman S., Rheinwald J.G.;
RT   "Cellular X-ray repair parameters of early passage squamous cell
RT   carcinoma lines derived from patients with known responses to
RT   radiotherapy.";
RL   Br. J. Cancer 49:595-601(1984).
//
RX   PubMed=7214336;
RA   Rheinwald J.G., Beckett M.A.;
RT   "Tumorigenic keratinocyte lines requiring anchorage and fibroblast
RT   support cultured from human squamous cell carcinomas.";
RL   Cancer Res. 41:1657-1663(1981).
//
RX   PubMed=8390283; DOI=10.1038/bjc.1993.238;
RA   Burns J.E., Baird M.C., Clark L.J., Burns P.A., Edington K.G.,
RA   Chapman C., Mitchell R., Robertson G., Soutar D., Parkinson E.K.;
RT   "Gene mutations and increased levels of p53 protein in human squamous
RT   cell carcinomas and their cell lines.";
RL   Br. J. Cancer 67:1274-1284(1993).
//
RX   PubMed=17312569; DOI=10.1002/hed.20478;
RA   Lin C.J., Grandis J.R., Carey T.E., Gollin S.M., Whiteside T.L.,
RA   Koch W.M., Ferris R.L., Lai S.Y.;
RT   "Head and neck squamous cell carcinoma cell lines: established models
RT   and rationale for selection.";
RL   Head Neck 29:163-188(2007).
//
RX   PubMed=20014447; DOI=10.1002/hed.21311;
RA   Tsui I.F.L., Garnis C.;
RT   "Integrative molecular characterization of head and neck cancer cell
RT   model genomes.";
RL   Head Neck 32:1143-1160(2010).
//
RX   PubMed=20145189; DOI=10.1158/1940-6207.CAPR-09-0076;
RA   Chakravarti N., Kadara H., Yoon D.-J., Shay J.W., Myers J.N., Lotan D.,
RA   Sonenberg N., Lotan R.;
RT   "Differential inhibition of protein translation machinery by curcumin
RT   in normal, immortalized, and malignant oral epithelial cells.";
RL   Cancer Prev. Res. (Philadelphia) 3:331-338(2010).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=21868764; DOI=10.1158/1078-0432.CCR-11-0690;
RA   Zhao M., Sano D., Pickering C.R., Jasser S.A., Henderson Y.C.,
RA   Clayman G.L., Sturgis E.M., Ow T.J., Lotan R., Carey T.E., Sacks P.G.,
RA   Grandis J.R., Sidransky D., Heldin N.-E., Myers J.N.;
RT   "Assembly and initial characterization of a panel of 85 genomically
RT   validated cell lines from diverse head and neck tumor sites.";
RL   Clin. Cancer Res. 17:7248-7264(2011).
//
RX   PubMed=22006338; DOI=10.1073/pnas.1114669108;
RA   Wang N.J., Sanborn Z., Arnett K.L., Bayston L.J., Liao W., Proby C.M.,
RA   Leigh I.M., Collisson E.A., Gordon P.B., Jakkula L.R., Pennypacker S.,
RA   Zou Y., Sharma M., North J.P., Vemula S.S., Mauro T.M., Neuhaus I.M.,
RA   LeBoit P.E., Hur J.S., Park K., Huh N., Kwok P.-Y., Arron S.T.,
RA   Massion P.P., Bale A.E., Haussler D., Cleaver J.E., Gray J.W.,
RA   Spellman P.T., South A.P., Aster J.C., Blacklow S.C., Cho R.J.;
RT   "Loss-of-function mutations in Notch receptors in cutaneous and lung
RT   squamous cell carcinoma.";
RL   Proc. Natl. Acad. Sci. U.S.A. 108:17761-17766(2011).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=24825747; DOI=10.1530/ERC-14-0102;
RA   Chang Y.-L., Hsu Y.-K., Wu T.-F., Huang C.-M., Liou L.-Y., Chiu Y.-W.,
RA   Hsiao Y.-H., Luo F.-J., Yuan T.-C.;
RT   "Regulation of estrogen receptor alpha function in oral squamous cell
RT   carcinoma cells by FAK signaling.";
RL   Endocr. Relat. Cancer 21:555-565(2014).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=29156801; DOI=10.18632/oncotarget.21174;
RA   Kalu N.N., Mazumdar T., Peng S.-H., Shen L., Sambandam V., Rao X.-Y.,
RA   Xi Y.-X., Li L.-R., Qi Y., Gleber-Netto F.O., Patel A., Wang J.,
RA   Frederick M.J., Myers J.N., Pickering C.R., Johnson F.M.;
RT   "Genomic characterization of human papillomavirus-positive and
RT   -negative human squamous cell cancer cell lines.";
RL   Oncotarget 8:86369-86383(2017).
//
RX   PubMed=30135316; DOI=10.1172/jci.insight.122204;
RA   Jamieson S.M.F., Tsai P., Kondratyev M.K., Budhani P., Liu A.,
RA   Senzer N.N., Chiorean E.G., Jalal S.I., Nemunaitis J.J., Kee D.,
RA   Shome A., Wong W.W., Li D., Poonawala-Lohani N., Kakadia P.M.,
RA   Knowlton N.S., Lynch C.R.H., Hong C.R., Lee T.W., Grenman R.,
RA   Caporiccio L., McKee T.D., Zaidi M., Butt S., Macann A.M.J.,
RA   McIvor N.P., Chaplin J.M., Hicks K.O., Bohlander S.K., Wouters B.G.,
RA   Hart C.P., Print C.G., Wilson W.R., Curran M.A., Hunter F.W.;
RT   "Evofosfamide for the treatment of human papillomavirus-negative head
RT   and neck squamous cell carcinoma.";
RL   JCI Insight 3:e122204.1-e122204.19(2018).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=30971826; DOI=10.1038/s41586-019-1103-9;
RA   Behan F.M., Iorio F., Picco G., Goncalves E., Beaver C.M.,
RA   Migliardi G., Santos R., Rao Y., Sassi F., Pinnelli M., Ansari R.,
RA   Harper S., Jackson D.A., McRae R., Pooley R., Wilkinson P.,
RA   van der Meer D.J., Dow D., Buser-Doepner C.A., Bertotti A., Trusolino L.,
RA   Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.;
RT   "Prioritization of cancer therapeutic targets using CRISPR-Cas9
RT   screens.";
RL   Nature 568:511-516(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//